The main objectives of this study are to determine the effect of elenestinib on the pharmacokinetic parameters (how the drug is absorbed, distributed, and processed by the body) of midazolam, and to determine the effect of elenestinib on the pharmacokinetic parameters of levonorgestrel/ethinyl estradiol, when given as a combined oral contraceptive. Healthy adult participants will receive midazolam and levonorgestrel/ethinyl estradiol with and without elenestinib and have blood samples taken.
Age range
18 Years – 65 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (AUC0-t)
Timeframe: Up to 27 days
Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf)
Timeframe: Up to 27 days
Percent of AUC0-inf extrapolated (AUC%extrap)
Timeframe: Up to 27 days
Maximum observed concentration (Cmax)
Timeframe: Up to 27 days
Time to reach Cmax (Tmax)
Timeframe: Up to 27 days
Apparent first-order terminal elimination half-life (t1/2)
Timeframe: Up to 27 days
Apparent total plasma clearance after oral administration (CL/F)
Timeframe: Up to 27 days
Apparent volume of distribution during the terminal elimination phase after oral administration (Vz/F)
Timeframe: Up to 27 days